Cheryl Lipson
Nephrology · Palmerton, PANPI 1447259478
Payments from drug & device makers
Across 66 payments — averaging $14.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$237
- GSK$157
- Pfizer$65
- Vifor Pharma, Inc.$53
- Mallinckrodt Enterprises LLC$47
- Amgen$45
- plus $339 from 15 others
What the payments were for
- Food & beverage$89295%
- Education$515%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 19 | $237 |
| GSK | 9 | $157 |
| Pfizer | 5 | $65 |
| Vifor Pharma, Inc. | 3 | $53 |
| Mallinckrodt Enterprises LLC | 2 | $47 |
| Amgen | 3 | $45 |
| AstraZeneca | 3 | $41 |
| Novartis | 2 | $29 |
| Boehringer Ingelheim | 2 | $29 |
| Lilly USA, LLC | 2 | $28 |
| Amarin Pharma, Inc. | 2 | $27 |
| Merck | 2 | $27 |
| Teva Pharmaceuticals USA, Inc. | 2 | $25 |
| Sanofi-aventis U.S. LLC | 2 | $25 |
| Akebia Therapeutics Inc | 2 | $21 |
| Fresenius USA Marketing, Inc. | 1 | $17 |
| Covidien LP | 1 | $17 |
| OPKO Pharmaceuticals, LLC | 1 | $16 |
| Otsuka America Pharmaceutical, Inc. | 1 | $14 |
| Radius Health, Inc. | 1 | $12 |
| AbbVie | 1 | $12 |
How this compares
$943 in reported general payments places this provider in the 55th percentile of 586 nephrology providers in Pennsylvania.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 51 | $48,082 |
| ProsolParenteral Amino Acid 20% No.1 | 42 | $7,185 |
| Midodrine Hcl | 11 | $1,601 |
| Losartan Potassium | 49 | $734 |
| Irbesartan | 26 | $705 |
| Labetalol Hcl | 11 | $690 |
| Metoprolol Succinate | 33 | $675 |
| Calcitriol | 29 | $443 |
| Atorvastatin Calcium | 14 | $377 |
| Torsemide | 15 | $314 |
| Valsartan | 13 | $280 |
| Amlodipine Besylate | 40 | $266 |
| Levothyroxine Sodium | 13 | $191 |
| Doxazosin Mesylate | 19 | $188 |
| Lisinopril | 16 | $176 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $29 | $48,08251 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 586 nephrology providers in Pennsylvania.
Other nephrology in Palmerton
- Katalin SusztakPhiladelphia$4.8M
- Debbie Cohen SteinPhiladelphia$2.8M
- Nelson KopytAllentown$2.1M
- Iris LeePhiladelphia$1.9M
- Abdallahsassine GearaPhiladelphia$1.2M
- Alexander ChangDanville$1000K
- Gaia MuallemPhiladelphia$942K
- Chike OkechukwuUpland$875K
- Christopher GislerPittsburgh$757K
- Umar FarooqHershey$723K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.